Douglas A Simonetto MD (He/Him)
Hepatology & Liver Transplantation
Associate Professor of Medicine
Join to View Full Profile
200 1st Street SWRochester, MN 55905
Dr. Simonetto is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Transplant Hepatology, 2015 - 2016- Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Gastroenterology, 2012 - 2015
- Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2009 - 2012
Hlth Scis Fed Univ Porto AlegreClass of 2007
Certifications & Licensure
MN State Medical License 2011 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Gastroenterology
- American Board of Internal Medicine Transplant Hepatology
Clinical Trials
- Acamprosate Safe to Use in Individuals With Liver Disease. Start of enrollment: 2020 Sep 21
Publications & Presentations
PubMed
- 1 citationsAcute kidney injury in severe alcohol-associated hepatitis treated with anakinra plus zinc or prednisone.Kavish R Patidar, Wanzhu Tu, Thomas G Cotter, Douglas A Simonetto, Amon Asgharpour
Hepatology. 2025-04-01 - Underrecognized association of porto-sinusoidal vascular disorder and telomere biology disorders.Puru Rattan, Kianna Nguyen, Daniel D Penrice, Davide Povero, Douglas A Simonetto
Journal of Hepatology. 2025-04-01 - Moderate alcohol-associated hepatitis: A real-world multicenter study.Francisco Idalsoaga, Luis Antonio Díaz, Winston Dunn, Heer Mehta, Karen Muñoz
Hepatology Communications. 2025-04-01
Journal Articles
- Comparison of Therapies for Primary Prevention of Esophageal Variceal Bleeding: A Systematic Review and Network Meta‐AnalysisDouglas A Simonetto, Mohammad Hassan Murad, Siddharth Singh, Patrick S Kamath, Hepatology
Press Mentions
PharmaIN Unveils Interim Phase 1b Clinical Data on the Activity and Safety of PHIN-214 in Decompensated Liver Cirrhosis at AASLD - the Liver Meeting® 2024November 18th, 2024- PharmaIN to Present Promising Interim Data from Its Ongoing Phase 1 Trial of PHIN-214, an Optimized Vasopressor for Decompensated Cirrhosis, at the Liver Meeting® 2024October 16th, 2024
- Surge in Alcohol-Related Disease During Pandemic Reveals Unmet Need for TreatmentMay 31st, 2022
- Join now to see all
Grant Support
- Liver Cirrhosis Network: Clinical Research Center - Mayo ClinicMAYO CLINIC ROCHESTER2021–2026
- Randomized Placebo Controlled Pilot Trial to determine the efficacy of an IL22 agonist (F-652) in patients with Alcoholic HepatitisMAYO CLINIC ROCHESTER2018–2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
